alexa

GET THE APP

Two Cases of Advanced Malignant Melanoma Occurring from the Esophagus | OMICS International| Abstract

Journal of Oncology Research and Treatment
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Case Report   
  • J Oncol Res Treat,
  • DOI: 10.4172/aot.s2.1000001

Two Cases of Advanced Malignant Melanoma Occurring from the Esophagus

Shuji Hiramoto1*, Ayako Kikuchi1, Tetsuso Hori2, Tamaoki Mikako3, Yuichi Yamagaa4, Go Hotta4, Yoko Mashimo3, Jyunya Tanaka3, Akira Yoshioka1, Naoki Yamashita2, Motoshige Nabeshima3, Masahiro Mizuno4, Yoshihiro Nishida5, Hajime Honjo5 and Chiharu Kawanami5
1Department of Clinical Oncology and Palliative Medicine, Mitsubishi Kyoto Hospital, Kyoto, Japan
2Department of Respiratory Surgeries, Mitsubishi Kyoto Hospital, Goshocho 1 Katsura Nishikyoku, Kyoto, Japan
3Department of Gastroenterology, Mitsubishi Kyoto Hospital, Goshocho 1 Katsura Nishikyoku, Kyoto, Japan
4Department of General Medicine, Mitsubishi Kyoto Hospital, Goshocho 1 Katsura Nishikyoku, Kyoto, Japan
5Department of Gastroenterology, Otsu Red Cross Hospital, Kyoto, Japan
*Corresponding Author : Shuji Hiramoto, Department of Clinical Oncology and Palliative Medicine, Mitsubishi Kyoto Hospital, Goshocho 1 Katsura Nishikyoku, Kyoto, Japan, Tel: +81-75-381-2111, Email: [email protected]

Abstract

We made a diagnosis as a malignant melanoma and conducted esophagectomy. She had DAC-Tam as a palliative chemotherapy after detecting recurrence. But she had wasted away and died within 14 months being diagnosed with her disease. Histological findings revealed malignant melanoma arise from esophagus with liver metastasis. She had nivolumab as first line therapy and ipilimumab subsequently, but she had wasted away and died within 6 months being diagnosed with her disease. Esophageal melanoma was very rare disease. Development of immune-check inhibitor and molecular targeting therapy changed the prognosis for patients.

Case-1

A 57-year-old woman was admitted with a complaint of fatigue and anemia (serum hemoglobin, 5.6 g/dl). We detected an irregular tumor 4 cm in diameter in the lower esophagus, using an upper endoscopic test; melanosis was detected near the tumor. An esophageal biopsy revealed large tumor cells possessing minimal cytoplasm and hyperchromatic indistinct nucleoli based on Hematoxylin and Eosin (HE) staining. We performed esophagectomy and the final staging, on histopathological examination, was IIIA (UICC-6). She was administered DAV-Feron (DTIC, ACNU, VCR and Interferonβ) as adjuvant chemotherapy. However, she was diagnosed with recurrence of the melanoma in the peritoneum in March 2010. We initiated DAM-Tam (DTIC, ACNU, CDDP and tamoxifen) as palliative chemotherapy. She had grade 3 neutropenia and grade 2 fatigues, but these adverse events were controlled to reduce dose settings. She progressively weakened and died within 14 months of being diagnosed with the disease.

Case-2

A 67-year-old woman visited complaining of fatigue. A type 1 tumor with blue pigment deposition in the lower esophagus was detected on upper endoscopy and liver metastasis was observed using Positron Emission Tomography-Computed Tomography (PET-CT). An esophageal biopsy revealed large tumor cells possessing minimal cytoplasm and hyperchromatic indistinct nucleoli based on HE staining. Immunostaining revealed that the tumor cells were positive for S-100 and Melan A, and negative for HMB-45. Histological findings revealed malignant melanoma that had arisen from the esophagus. We initiated nivolumab therapy based on the negative results of the B-RAF V600E mutational test. She exhibited no adverse events after the administration of nivolumab. However, CT revealed progression of the disease within 3 months. We changed to ipillimumab. However, she progressively weakened and died within 6 months of being diagnosed with the disease. Esophageal melanoma was very rare disease. Development of immune-check inhibitor and molecular targeting therapy changed the prognosis for patients.

Keywords: Melanoma; Esophageal cancer; Molecule targeting therapy; Immune-check point inhibitor

Citation: Hiramoto S, Kikuchi A, Hori T, Mikako T, Yamaga Y, et al. (2021) Two Cases of Advanced Malignant Melanoma Occurring from the Esophagus. J Oncol Res Treat S2:001. Doi: 10.4172/aot.s2.1000001

Copyright: © 2021 Hiramoto S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Article Usage
  • Total views: 308
  • [From(publication date): 0-0 - Sep 26, 2021]
  • Breakdown by view type
  • HTML page views: 154
  • PDF downloads: 154
Top